Home health remedies Pfizer’s Upjohn strikes generic Viagra deal with telehealth provider Roman

Pfizer’s Upjohn strikes generic Viagra deal with telehealth provider Roman

22
0
SHARE

Despite positive signs that Pfizer’s Mylan-partnered spinoff of generics business Upjohn could be a win for all parties, uncertainty has clouded the new company’s future. Now, at least one thing will be certain: It’ll have a buyer for generic Viagra––and an unconventional one at that. 

Greenstone, the U.S. subsidiary of Pfizer’s Upjohn, has reached an exclusive supply deal with telehealth provider Roman for access to Pfizer’s FDA-approved generic of erectile dysfunction med Viagra (sildenafil citrate). 

Under the agreement, Roman will source the generic exclusively through Greenstone with the drug being manufactured in the same European facilities as branded Viagra at no extra cost to Roman subscribers, Pfizer said in a release. Roman is a subsidiary of telehealth provider Ro specializing in men’s health, Pfizer said.

Pfizer’s decision to provide generic Viagra exclusively to Roman comes as the drugmaker prepares for its much-ballyhooed Upjohn spinoff with generics giant Mylan. 

Without Upjohn in the fold, Pfizer is expecting a more mainstreamed business in the coming years, with RBC Capital Markets analyst Randall Stanicky predicting the drugmaker is “set to emerge is a best-in-class growth story on [its] smaller, more innovative base,” in a note to investors earlier this month.

Between 2021 and 2025, Pfizer could see 6% annual revenue growth based on the strength of its “core five” products, comprising rare-disease med Vyndaqel, cancer-fighter Ibrance, anti-inflammatory therapy Xeljanz, next-gen anticoagulant Eliquis and vaccine giant Prevnar, Stanicky figures. He pointed in particular to targeted therapy Vyndaqel, which could see strong uptake in transthyretin amyloid cardiomyopathy (ATTR-CM) and become one of Pfizer’s “most important drivers” this year. 

Those five products don’t face a meaningful patent loss until after 2025, Stanicky noted, giving Pfizer plenty of room to identify a strategic buy or invest further into its pipeline to keep growth on the uptick in the following years. 

RELATED: Read may say goodbye to Pfizer, but he’ll join the board at spinoff Viatris

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

four × 2 =